Group 1 - The company, Guangzhou Maipu Regenerative Medicine Technology Co., Ltd., plans to acquire 100% equity of Yijie Medical through a combination of issuing shares and cash payment [9][29] - The target company, Yijie Medical, specializes in the research, production, and sales of neuro-interventional medical devices, including neuro-interventional catheters and guidewires [9][18] - The transaction aims to expand the company's product portfolio and enhance its market position in the neuro-interventional field, which is experiencing significant growth due to increasing demand for innovative treatment options for cerebrovascular diseases [30][31] Group 2 - The market for neurovascular interventional medical consumables in China is projected to grow from 3.2 billion RMB in 2017 to 43.2 billion RMB by 2028, with a compound annual growth rate (CAGR) of 36.5% [30][31] - The company has established a strong distribution network, collaborating with nearly 1,000 distributors and entering approximately 2,000 hospitals across China, which will facilitate the integration of sales channels post-acquisition [18][29] - The acquisition aligns with national policies encouraging mergers and acquisitions to enhance the quality and competitiveness of listed companies, thereby supporting the company's strategic growth objectives [31]
迈普医学: 广州迈普再生医学科技股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易预案（修订稿）